不受控制的炎症是许多疾病发展的关键因素。基于天然来源的抗炎分子正在积极研究,其中阿里斯蒂达·德莱萨·雷茨(Ar。dp)传统上被用作治疗炎症的糊剂。本研究旨在评估抗炎,镇痛药,通过一系列体内和体外模型,A.depressa的乙醇提取物的解热潜力。通过浸渍法制备了A的乙醇提取物,并使用高效液相色谱法进行了化学表征,显示槲皮素的存在,香草酸,绿原酸,对香豆酸,m-香豆酸,阿魏酸,肉桂酸,和芥子酸;然后用DPPH体外试验筛选其抗氧化能力,这表明了中等的清除能力。接下来进行蛋白质变性测定以评估Ar的体外抗炎潜力。dp,与标准药物(双氯芬酸钠)相比,显示出显着的抑制作用(44.44%),在1mg/mL的浓度下具有89.19%的抑制作用。Ar的体内安全性。根据OECD-425急性毒性指南评估dp,发现最高5g/kg是安全的。Ar的体内抗炎潜力。dp在急性(角叉菜胶引起的水肿:84.60%,三种不同的剂量(125,250和500mg/kg)进行了评估,组胺诱导的爪水肿:84%),亚慢性(棉花颗粒引起的肉芽肿:57.54%),和慢性(完全弗氏佐剂诱导的关节炎:82.2%)模型。我们的结果表明Ar。在急性和慢性模型中,dp比双氯芬酸钠具有显着(p<0.05)的抗炎作用。组织病理学研究表明Ar中炎性细胞的爪组织浸润减少。dp处理的动物。同样,A.dp以时间依赖性方式显示出显着(p<0.05)的镇痛(酵母诱导的发热模型:23.53%)和解热(乙酸诱导的扭体模型:51%)作用。关于COX-1和COX-2与先前提到的八个配体的相互作用的计算机研究证实了对负责炎症和发烧的酶的抑制。根据本研究的结果,结论是Ar。dp有抗炎作用,镇痛药,和解热特性可能与其药理活性酚类生物活性分子有关。
Uncontrolled inflammation is a crucial factor in the development of many diseases. Anti-inflammatory molecules based on natural sources are being actively studied, among which Aristida depressa Retz (Ar.dp) has been traditionally used as a paste to heal inflammation. The present study aimed to evaluate the anti-inflammatory,
analgesic, and antipyretic potential of an ethanolic extract of A. depressa through a battery of in vivo and in vitro models. The ethanolic extract of A. depressa was prepared by maceration and chemically characterized using high-performance liquid chromatography, which revealed the presence of quercetin, vanillic acid, chlorogenic acid, p-coumaric acid, m-coumaric acid, ferulic acid, cinnamic acid, and sinapic acid; its antioxidant capacity was then screened with the DPPH in vitro assay, which indicated moderate scavenging capacity. A protein denaturation assay was next performed to evaluate the in vitro anti-inflammatory potential of Ar.dp, which showed significant inhibition (44.44%) compared to the standard drug (diclofenac sodium), with 89.19% inhibition at a concentration of 1 mg/mL. The in vivo safety profile of Ar.dp was evaluated in accordance with the OECD-425 acute toxicity guidelines and found to be safe up to 5 g/kg. The in vivo anti-inflammatory potentials of Ar.dp were evaluated at three different doses (125, 250, and 500 mg/kg) in acute (carrageenan-induced edema: 84.60%, histamine-induced paw edema: 84%), sub-chronic (cotton-pellet-induced granuloma: 57.54%), and chronic (complete-Freund\'s-adjuvant-induced arthritis: 82.2%) models. Our results showed that Ar.dp had significant (p < 0.05) anti-inflammatory effects over diclofenac sodium in the acute and chronic models. Histopathology studies indicated reduced infiltration of paw tissues with inflammatory cells in Ar.dp-treated animals. Similarly, Ar.dp showed significant (p < 0.05)
analgesic (yeast-induced-pyrexia model: 23.53%) and antipyretic (acetic-acid-induced writhing model: 51%) effects in a time-dependent manner. In silico studies on the interactions of COX-1 and COX-2 with the eight ligands mentioned earlier confirmed the inhibition of enzymes responsible for inflammation and fever. Based on the findings of the present study, it is concluded that Ar.dp has anti-inflammatory,
analgesic, and antipyretic properties that are likely linked to its pharmacologically active phenolic bioactive molecules.